EDAP TMS SA, the global leader in therapeutic ultrasound, today announced the first successful treatments performed at Germany's Mannheim University Hospital ("UMM"), using the Company's Focal One® HIFU device.
UMM is home to one of the largest urological Centers in Germany, with more than 4,000 patients treated annually. The Department of Urology at UMM is headed by prominent urologist Pr. M.S. Michel, also Chairman of the Academy of German Urologists. The UMM Urology Department is a large certified prostate cancer center, offering the most advanced innovative imaging and therapeutic technologies to address prostate cancer.
Pr. Michel commented: "HIFU with Focal One, together with its innovative MRI - ultrasound image fusing capabilities, is definitely the most promising therapy for men with early stage prostate cancer; UMM is proud to be one of the early adopters of this revolutionary device, and among the first in the world to offer this therapeutic option to prostate cancer patients."
Marc Oczachowski, EDAP's Chief Executive Officer, added, "We are very pleased to add one of the largest German Prostate Cancer Centers, Mannheim University Hospital, to our growing number of Focal One adopters. This trend confirms the positioning of our Focal One HIFU system as a viable complement to current prostate cancer treatments at leading Institutions."
EDAP TMS recently presented its innovative technologies at the 66th Congress of the German Society of Urology held October 1 - 4, 2014, in Dusseldorf, Germany. The Company's presentation included live Focal One demonstrations, which were well-attended by urologists. Feedback from the demonstrations confirmed significant physician interest in adopting this HIFU tool to address the needs of prostate cancer patients.